{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=47",
    "query": {
      "intervention": "Combination Agent",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 5568,
    "total_pages": 557,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T19:01:22.492Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02131272",
      "title": "A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin detemir",
          "type": "DRUG"
        },
        {
          "name": "Insulin NPH",
          "type": "DRUG"
        },
        {
          "name": "Diet/exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-06-11",
      "completion_date": "2016-06-14",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02131272"
    },
    {
      "nct_id": "NCT00707239",
      "title": "Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia, Bacterial"
      ],
      "interventions": [
        {
          "name": "tigecycline",
          "type": "DRUG"
        },
        {
          "name": "imipenem/cilastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2008-12",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-07-10",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707239"
    },
    {
      "nct_id": "NCT01466569",
      "title": "An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor of Epithelial Origin",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "AbGn-7",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbGenomics B.V Taiwan Branch",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2011-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2015-06-23",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 2,
      "location_summary": "Rockledge, Pennsylvania • San Antonio, Texas",
      "locations": [
        {
          "city": "Rockledge",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01466569"
    },
    {
      "nct_id": "NCT04272645",
      "title": "Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab 1200 MG in 20 ML Injection",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib 150 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2020-10",
      "completion_date": "2022-10",
      "has_results": false,
      "last_update_posted_date": "2020-07-15",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04272645"
    },
    {
      "nct_id": "NCT02075112",
      "title": "Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Soy isoflavone",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-11",
      "completion_date": "2019-09",
      "has_results": false,
      "last_update_posted_date": "2019-12-06",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02075112"
    },
    {
      "nct_id": "NCT04936841",
      "title": "Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-214",
          "type": "DRUG"
        },
        {
          "name": "anti-PD-1 therapy",
          "type": "DRUG"
        },
        {
          "name": "Palliative Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-08-05",
      "completion_date": "2022-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04936841"
    },
    {
      "nct_id": "NCT02343666",
      "title": "HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus 1 Positive",
        "Stage I Adult Hodgkin Lymphoma",
        "Stage I Adult Non-Hodgkin Lymphoma",
        "Stage II Adult Hodgkin Lymphoma",
        "Stage II Adult Non-Hodgkin Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Non-Hodgkin Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "O6-Benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-08-15",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343666"
    },
    {
      "nct_id": "NCT00324831",
      "title": "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "Intervention/procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "antibody therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biological therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "chemotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "colony-stimulating factor therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "cytokine therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "monoclonal antibody therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "non-specific immune-modulator therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "tumor cell derivative vaccine",
          "type": "PROCEDURE"
        },
        {
          "name": "vaccine therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Favrille",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 2,
      "location_summary": "Beverly Hills, California • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324831"
    },
    {
      "nct_id": "NCT07777822",
      "title": "Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NSCLC",
        "Non-small Cell Lung Cancer",
        "Non-Small Cell Lung Cancer NSCLC",
        "Non-Squamous Non Small Cell Lung Cancer",
        "Lung Cancer (NSCLC)",
        "Metastatic NSCLC - Non-Small Cell Lung Cancer",
        "Metastatic Non-Squamous Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "zoldonrasib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed + cisplatin /carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 430,
      "start_date": "2026-08-14",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 4,
      "location_summary": "Anchorage, Alaska • Fort Lauderdale, Florida • Plantation, Florida",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07777822"
    },
    {
      "nct_id": "NCT00075231",
      "title": "A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Kaletra® (lopinavir/ritonavir)",
          "type": "DRUG"
        },
        {
          "name": "Combivir® (lamivudine, zidovudine)",
          "type": "DRUG"
        },
        {
          "name": "Sustiva® (efavirenz)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2003-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-10-02",
      "last_synced_at": "2026-11-15T19:01:22.492Z",
      "location_count": 1,
      "location_summary": "Fountain Valley, California",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00075231"
    }
  ]
}